Day Two

• Evaluating consumer commercialization approaches to identifying scalable market adoption strategies for LBP & FMT developers
• Assessing reimbursement-driven therapeutic models to determining long-term revenue generation opportunities across microbiome markets
• Identifying customer engagement techniques to strengthening awareness, retention & downstream therapeutic demand

• Implementing longitudinal and interventional study designs to move beyond correlation and establish causative links required for clinical validation
• Prioritising investment into complex, large-scale trials to demonstrate sustained therapeutic impact across chronic indications and long-term outcomes
• Integrating multi-disciplinary capabilities and datasets to build rigorous, evidence-driven development strategies that support regulatory approval

• Challenging the bias toward curative medicine by demonstrating how probiotics and prebiotics deliver measurable preventive health benefits including cognitive decline prevention and gut microbiota restoration
• Addressing regulatory gaps created by insufficient evidence standards that allow unsubstantiated probiotic claims to undermine scientifically credible preventive microbiome interventions
• Improving scientific communication of existing probiotic and prebiotic research to build clinical and regulatory credibility for preventive medicine applications in mainstream healthcare

Measuring complex, multi-strain microbiome products remains inconsistent, with biased culture assays, unclear regulatory expectations, and no validated industry standards. This workshop shows how to adopt novel assay technologies and build product-specific analytical strategies that demonstrate identity, potency, and viability, enabling confident regulatory interactions.

Workshop highlights:

• Assessing emerging technologies that quantify complex microbial consortia while capturing strain level identity and live viability without biased culture workflows
• Defining product-specific analytical strategies aligned with evolving FDA expectations to validate potency identity and release assays across development stages
• Comparing approaches to measure multi-strain abundance and function including sequencing viability assays and synthetic biology readouts to strengthen mechanism claims
• Walking through end-to-end processes for selecting labs piloting methods and validating assays to generate reproducible data satisfying regulators

• Benchmarking regulatory pathways used across FDA, EMA & national authorities to clarify expectations and reduce trial approval uncertainty
• Comparing real-world regulatory interactions including key questions, feedback loops & submission strategies to strengthen future applications
• Identifying common pitfalls in CMC, trial design & product characterisation to proactively mitigate delays in regulatory approval processes

• Addressing misconceptions around FDA regulatory expectations to demonstrate that flexible, product-specific approaches are preferred over rigid standardization frameworks for complex microbiome products
• Examining why standardizing assays and release specifications across highly variable live biotherapeutic products is impractical and how product-specific strategies accelerate development timelines
• Encouraging open sharing of assay approaches and development experiences across the industry to build collective knowledge and enable more practical regulatory strategies for diverse microbiome products

• Understanding critical US and EU market regulatory differences, including SoHO, to streamline market entry and avoid delays
• Navigating complexities of establishing European trial sites and novel regulatory pathways to de-risk therapeutic development investment effectively
• Outlining key strategies for successfully introducing an approved US drug into the European market to ensure effective penetration

• Examining mechanism of action data from microbiome therapeutic programs to build evidence-based narratives that strengthen regulatory and pharma partnership credibility
• Leveraging pharmacokinetic and engraftment data from clinical trials to deepen process understanding and demonstrate reproducible therapeutic activity in target indications
• Applying mechanistic insights from donor-derived and defined consortium programs to inform next-generation microbiome therapeutic development strategies

• Examining host mechanisms regulating microbiota through mucosal barrier signaling to identify key interactions governing microbial behavior and community composition
• Investigating how microbiota degrade and interact with mucus signals to understand bidirectional communication pathways driving healthy and dysbiotic microbiome states
• Leveraging synthetic mucin technology to re-engineer host-microbiota signaling and improve live biotherapeutic engraftment and phenotypic modulation at mucosal sites

• Explaining the contribution of gut microbiota to neurologic symptoms
• Use a pharmacological framework in the development of fecal microbiota live biotherapeutic products
• Present clinical evidence of durable therapeutic benefits of targeting the gut microbiome with microbiota transplant therapy